PATENT CLAIM ANALYSIS

Application Number: 15887456
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "277100"]

Abstract:
A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.

Claim (Index 5):
The method of  claim 4 , wherein said solid tumor is selected from the group consisting of breast cancer, lung cancer, colon cancer, pancreatic cancer, renal cancer, stomach cancer, liver cancer, bone cancer, neural tissue cancer, melanoma, ovarian cancer, testicular cancer, prostate cancer, cervical cancer, vaginal cancer, and bladder cancer.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 88.0
- Lexical Diversity: 1.49333
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14021353', '15016375', '12933567', '11773162', '14158531']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.754827386774414
- 35 USC 102 Novelty (BERT): 0.5267861009623741
- Combined Prediction Score: 0.73202325819321
- Mean Citation Score: 320.313956
- Max Citation Score: 332.7924
- Similarity Product: 188.2291593461752

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test